Targeted protein degradation has recently gained widespread interest as both a novel
therapeutic strategy and a useful tool in biomedical research. Targeted protein degraders …

Targeted protein degradation (TPD) is a rapidly developing field in chemical biology and
drug discovery. Various TPD modalities have emerged, with proteolysis-targeting chimeras …

Repurposing E3 ubiquitin ligases for targeted protein degradation via customized molecular
glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic …

The design of proteolysis-targeting chimeras (PROTACs) is a powerful small-molecule
approach for inducing protein degradation. PROTACs conjugate a target warhead to an E3 …

Targeted protein degradation mediated by small molecule degraders represents an exciting
new therapeutic opportunity to eliminate disease-causing proteins. These molecules recruit …

Ubiquitin-like proteins (UBLs) are conjugated by dynamic E1–E2–E3 enzyme cascades. E1
enzymes activate UBLs by catalysing UBL carboxy-terminal adenylation, forming a covalent …

Targeted protein degradation with proteolysis targeting chimeras (PROTACs) is a powerful
therapeutic modality for eliminating disease-causing proteins through targeted ubiquitination …

Targeted protein degradation is a promising area in the discovery and development of
innovative therapeutics. Molecular glues mediate proximity-induced protein degradation and …

Targeted protein degradation compounds, including molecular glues or proteolysis targeting
chimeras, are an exciting new therapeutic modality in small molecule drug discovery. This …

Targeted protein degradation has arisen as a powerful strategy for drug discovery allowing
the targeting of undruggable proteins for proteasomal degradation. This approach most …